Primary tumor resection followed by PRRT in the treatment of patients with metastatic neuroendocrine ileal cancer – Preliminary data from a retrospective single center study

#3884

Introduction: A low volume disease is an independent positive prognostic factor for the evaluation of response to peptides-radiolabelled-receptor-therapy (PRRT). Data from a previous study in patients with pancreatic-neuroendocrine-cancer (P-NET) have shown that resection of the primary tumor before PRRT improves response to therapy and increases progression-free survival (PFS).

Aim(s): Primary aim was to evaluate the difference in two cohorts of patients (surgery + PRRT vs. PRRT alone) in terms of PFS. Secondary aim was to evaluate the safety of the treatment in this clinical setting.

Materials and methods: From 2000 to 2016, patients with G1-G2 grade neuroendocrine ileal cancer with synchronous liver metastasis, not eligible for radical surgery but eligible for PRRT, were retrospectively enrolled. Two groups with a comparable total volume disease have been identified: Patients underwent resection of primary cancer before PRRT (group A) and patients underwent only PRRT (group B). The PFS of the two groups has been compared with a mean of 60 months of follow-up (range 6-132 months).

Conference:

Presenting Author: Francesco M

Authors: Mattana F, Zuccotti G, Barone A, Muraglia L, Travaini L,

Keywords: neuroendocrine neoplasm, nuclear medicine, surgery, PRRT, GEP-NET, ileal neoplasm,